These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11366473)

  • 1. Updates from the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Whitson S
    Posit Aware; 1998; 9(6):18-9. PubMed ID: 11366473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients.
    Hewitt RG; Shelton MJ; Esch LD
    AIDS; 1999 May; 13(7):868-9. PubMed ID: 10357393
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV and hepatitis C virus co-infection.
    Sulkowski M
    Hopkins HIV Rep; 1998 Nov; 10(6):8, 12. PubMed ID: 11366132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir, triglycerides, and pancreatitis.
    Perry RC; Cushing HE; Deeg MA; Prince MJ
    Clin Infect Dis; 1999 Jan; 28(1):161-2. PubMed ID: 10028103
    [No Abstract]   [Full Text] [Related]  

  • 5. After the drugs: what's next?
    Schouten JT
    Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highlights of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
    Prescott LM
    Body Posit; 2002 Dec; 15(7):16-20. PubMed ID: 14989207
    [No Abstract]   [Full Text] [Related]  

  • 7. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Newsline People AIDS Coalit N Y; 1998 Dec; ():16-8. PubMed ID: 11367083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy: rehashes, leftovers, and a pinch of new data.
    Gallant JE
    Hopkins HIV Rep; 1998 Nov; 10(6):1, 4, 9-11. PubMed ID: 11366128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Managing HIV infection. 2 new aspects].
    Katlama C
    Presse Med; 1999 Nov; 28 Suppl 3():11-4. PubMed ID: 10605461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked hypertriglyceridaemia associated with ritonavir therapy.
    Sullivan AK; Feher MD; Nelson MR; Gazzard BG
    AIDS; 1998 Jul; 12(11):1393-4. PubMed ID: 9708422
    [No Abstract]   [Full Text] [Related]  

  • 12. Notes from the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2002.
    Susman E
    AIDS; 2003 Jan; 17(2):N1-2. PubMed ID: 12545099
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
    Nolan DP; O'Connor MB; O'Connor C; Moriarty M; O'Leary A; Bergin C
    Int J STD AIDS; 2010 Jan; 21(1):75-6. PubMed ID: 19884356
    [No Abstract]   [Full Text] [Related]  

  • 14. Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
    Prescott LM
    Body Posit; 1998 Dec; 11(12):11-2. PubMed ID: 11366134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV therapy trials: new studies and follow-up of existing trials.
    Bartnof HS
    BETA; 1999; 12(4):58-60. PubMed ID: 11367257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    ;
    HIV Med; 2000 Mar; 1(2):76-101. PubMed ID: 11737331
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
    Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
    Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. . . . from the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Res Initiat Treat Action; 1999 Dec; 5(5):16-21. PubMed ID: 11366886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-full or half-empty: no simple answer on protease inhibitor failure.
    Torres G
    GMHC Treat Issues; 1997 Oct; 11(10):1-2. PubMed ID: 11364818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.